BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26487643)

  • 21. ABCB1 gene polymorphisms are not associated with treatment outcome in elderly acute myeloid leukemia patients.
    van der Holt B; Van den Heuvel-Eibrink MM; Van Schaik RH; van der Heiden IP; Wiemer EA; Vossebeld PJ; Löwenberg B; Sonneveld P
    Clin Pharmacol Ther; 2006 Nov; 80(5):427-39. PubMed ID: 17112800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia.
    Verstovsek S; Manshouri T; Smith FO; Giles FJ; Cortes J; Estey E; Kantarjian H; Keating M; Jeha S; Albitar M
    Cancer; 2003 May; 97(9):2212-7. PubMed ID: 12712473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and tolerability of gemtuzumab ozogamicin (anti-CD33 monoclonal antibody, CMA-676, Mylotarg) in children with relapsed/refractory myeloid leukemia.
    Brethon B; Auvrignon A; Galambrun C; Yakouben K; Leblanc T; Bertrand Y; Leverger G; Baruchel A
    BMC Cancer; 2006 Jun; 6():172. PubMed ID: 16805911
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program.
    Willman CL
    Semin Hematol; 1997 Oct; 34(4 Suppl 5):25-33. PubMed ID: 9408958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of miR-210 is Associated with Poor Prognosis of Acute Myeloid Leukemia.
    Tang X; Chen L; Yan X; Li Y; Xiong Y; Zhou X
    Med Sci Monit; 2015 Nov; 21():3427-33. PubMed ID: 26549593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
    El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
    Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
    Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
    Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia.
    Brown FC; Still E; Koche RP; Yim CY; Takao S; Cifani P; Reed C; Gunasekera S; Ficarro SB; Romanienko P; Mark W; McCarthy C; de Stanchina E; Gonen M; Seshan V; Bhola P; O'Donnell C; Spitzer B; Stutzke C; Lavallée VP; Hébert J; Krivtsov AV; Melnick A; Paietta EM; Tallman MS; Letai A; Sauvageau G; Pouliot G; Levine R; Marto JA; Armstrong SA; Kentsis A
    Cancer Discov; 2018 Apr; 8(4):478-497. PubMed ID: 29431698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group.
    Gerbing RB; Alonzo TA; Sung L; Gamis AS; Meshinchi S; Plon SE; Bertuch AA; Gramatges MM
    J Clin Oncol; 2016 Nov; 34(31):3766-3772. PubMed ID: 27354474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multidrug resistance-associated protein in acute myeloid leukemia: No impact on treatment outcome.
    Filipits M; Suchomel RW; Zöchbauer S; Brunner R; Lechner K; Pirker R
    Clin Cancer Res; 1997 Aug; 3(8):1419-25. PubMed ID: 9815827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relevance of renin expression by real-time PCR in acute myeloid leukemia.
    Iñigo Sde L; Casares MT; Jorge CE; Leiza SM; Santana GS; Bravo de Laguna SJ; San Miguel JD; Caballero A; Alvarez Mdel M; Castellano AL; Henríquez HL; Labarta TM
    Leuk Lymphoma; 2006 Mar; 47(3):409-16. PubMed ID: 16396763
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study.
    Marcucci G; Baldus CD; Ruppert AS; Radmacher MD; Mrózek K; Whitman SP; Kolitz JE; Edwards CG; Vardiman JW; Powell BL; Baer MR; Moore JO; Perrotti D; Caligiuri MA; Carroll AJ; Larson RA; de la Chapelle A; Bloomfield CD
    J Clin Oncol; 2005 Dec; 23(36):9234-42. PubMed ID: 16275934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The clinical significance of real-time fluorescence PCR quantification of hepatocyte growth factor mRNA expression in acute leukemia].
    Cen D; Lü JX; Pei RZ; Tu ZG; Yu XL; Wen YA
    Zhonghua Nei Ke Za Zhi; 2008 May; 47(5):401-4. PubMed ID: 18953951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.
    Ravindranath Y; Chang M; Steuber CP; Becton D; Dahl G; Civin C; Camitta B; Carroll A; Raimondi SC; Weinstein HJ;
    Leukemia; 2005 Dec; 19(12):2101-16. PubMed ID: 16136167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of myeloperoxidase expression in childhood acute myeloid leukemia.
    Roberson JR; Onciu M; Pounds S; Rubnitz JE; Pui CH; Razzouk BI
    Pediatr Blood Cancer; 2008 Mar; 50(3):542-8. PubMed ID: 17763467
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Phase I Study of Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Dose Escalation of Targeted Consolidation Immunotherapy with Gemtuzumab Ozogamicin in Children and Adolescents with CD33+ Acute Myeloid Leukemia.
    Zahler S; Bhatia M; Ricci A; Roy S; Morris E; Harrison L; van de Ven C; Fabricatore S; Wolownik K; Cooney-Qualter E; Baxter-Lowe LA; Luisi P; Militano O; Kletzel M; Cairo MS
    Biol Blood Marrow Transplant; 2016 Apr; 22(4):698-704. PubMed ID: 26785332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myocyte enhancer factor 2C in hematopoiesis and leukemia.
    Canté-Barrett K; Pieters R; Meijerink JP
    Oncogene; 2014 Jan; 33(4):403-10. PubMed ID: 23435431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group.
    Ho PA; Kuhn J; Gerbing RB; Pollard JA; Zeng R; Miller KL; Heerema NA; Raimondi SC; Hirsch BA; Franklin JL; Lange B; Gamis AS; Alonzo TA; Meshinchi S
    J Clin Oncol; 2011 Feb; 29(6):704-11. PubMed ID: 21189390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
    Creutzig U; Büchner T; Sauerland MC; Zimmermann M; Reinhardt D; Döhner H; Schlenk RF
    Cancer; 2008 Feb; 112(3):562-71. PubMed ID: 18076087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.
    Lapillonne H; Renneville A; Auvrignon A; Flamant C; Blaise A; Perot C; Lai JL; Ballerini P; Mazingue F; Fasola S; Dehée A; Bellman F; Adam M; Labopin M; Douay L; Leverger G; Preudhomme C; Landman-Parker J
    J Clin Oncol; 2006 Apr; 24(10):1507-15. PubMed ID: 16575000
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.